Skip to content

Belite Bio

US · BLTE #1866 by market cap Listed 2022
156.08 +0.47 +0.30%
Live - 5344 symbols - heartbeat 477s ago · 2026-10-08 06:30
Pre-market 155.99 -0.06%
After-hours 156.08 0.00%
Market cap
6.29B
P/B
8.09
EPS
-2.31
Reader sentiment Are you bullish or bearish on BLTE?

Anonymous reader poll. Unscientific, not investment advice.

✦ Quant Ownership Signal how this is computed

Mixed / stable
  • Total institutional ownership (as a % of shares) was little changed.

Institutional ownership

Held by institutions
66.24%
Institutions
92
As of
2026/Q3 vs. prior period

Holder types

Public Company43.85%
Hedge Fund18.75%
Mutual Fund2.29%
Individual/Insider1.36%
VC/PE Fund0.71%
Private Company0.37%
Family Office/Trust0.27%
Other32.40%

Top holders as of 2026-02-28

Lin BioScience, Inc. 42.45% · 17.10M sh
Darwin Global Management Limited 7.64% · 3.08M sh
Paradigm Biocapital Advisors LP 3.06% · 1.23M sh
RTW Investments, LP 1.78% · 715.33K sh
Millennium Management LLC 1.23% · 494.56K sh
Maverick Capital, Ltd. 0.98% · 396.31K sh
Eventide Asset Management, LLC 0.97% · 390.83K sh
Deerfield Management Company, L.P. 0.89% · 357.20K sh
Yu-Hsin Lin 0.63% · 253.08K sh
Holocene Advisors, LP 0.62% · 251.04K sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 7 buys · 29 sells

NameRoleStake
Yu-Hsin Lin Chairman of the Board of Directors & CEO 0.63%
Hao-Yuan Chuang Chief Financial Officer 0.57%
Wan-Shan Chen Director 0.08%
Nathan Mata Chief Scientific Officer 0.04%
Hendrik Scholl Member of Ophthalmology Clinical Advisory Board 0.04%
Xiao-Hui Chen Director 0.00%
Wei-Cheng Liaw -- --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-09-07 Hao-Yuan Chuang Chief Financial Officer Automatic Disposition -67,395 $180.16–198.05
2026-09-07 Yu-Hsin Lin Chairman of the Board of Directors & CEO Automatic Disposition -100,435 $180.29–198.09
2026-08-11 Hao-Yuan Chuang Chief Financial Officer Automatic Disposition -367 $180.00–180.57
2026-08-11 Yu-Hsin Lin Chairman of the Board of Directors & CEO Automatic Disposition -365 $180.00–180.57
2026-06-17 Hendrik Scholl Member of Ophthalmology Clinical Advisory Board Private Disposition -10,000 $143.90–147.11
2026-06-15 Hendrik Scholl Member of Ophthalmology Clinical Advisory Board Private Disposition -10,000 $137.61–145.02
2026-05-06 Nathan Mata Chief Scientific Officer Automatic Disposition -666 $152.45–155.25
2026-05-05 Nathan Mata Chief Scientific Officer Automatic Disposition -1,000 $151.57–156.00
2026-05-04 Nathan Mata Chief Scientific Officer Automatic Disposition -1,000 $153.92–158.11
2026-05-03 Nathan Mata Chief Scientific Officer Automatic Disposition -1,000 $153.50–157.49
2026-04-30 Nathan Mata Chief Scientific Officer Automatic Disposition -1,000 $153.89–160.00
2026-04-29 Nathan Mata Chief Scientific Officer Automatic Disposition -1,000 $155.68–158.15
2026-04-28 Nathan Mata Chief Scientific Officer Automatic Disposition -1,000 $154.58–158.19
2026-04-27 Nathan Mata Chief Scientific Officer Automatic Disposition -1,000 $154.65–162.14
2026-04-26 Nathan Mata Chief Scientific Officer Automatic Disposition -1,000 $160.83–164.07
2026-04-23 Nathan Mata Chief Scientific Officer Automatic Disposition -1,000 $157.86–162.53
2026-04-22 Nathan Mata Chief Scientific Officer Automatic Disposition -1,000 $164.47–169.56
2026-04-21 Nathan Mata Chief Scientific Officer Automatic Disposition -1,000 $165.70–173.04
2026-04-20 Nathan Mata Chief Scientific Officer Automatic Disposition -1,000 $163.49–167.34
2026-04-20 Hendrik Scholl Member of Ophthalmology Clinical Advisory Board Other Derivative Acquisition +10,000 $77.40

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-10-08 06:30:46 · For reference only, not investment advice and not tailored to your situation.